medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2011, Número 09

<< Anterior Siguiente >>

Ginecol Obstet Mex 2011; 79 (09)


La anticoncepción hormonal como factor de riesgo para cáncer cervicouterino: evidencias biológicas, inmunológicas y epidemiológicas

Castro RJI, Hernández GC, Madrid MV

Idioma: Español
Referencias bibliográficas: 46
Paginas: 537-543
Archivo PDF: 183.75 Kb.


RESUMEN

Antecedentes: el cáncer cervicouterino ha sido ampliamente estudiado, al igual que los diversos factores de riesgo para padecerlo. Uno de esos factores es el uso prolongado de anticonceptivos hormonales.
Objetivo: reportar los hallazgos biológicos, inmunológicos y epidemiológicos derivados del uso de anticonceptivos orales y su relación con el cáncer cervicouterino.
Material y método: estudio retrospectivo efectuado con base en la información publicada en la bibliografía nacional e internacional.
Conclusiones: persiste la controversia entre los datos epidemiológicos y los biológicos experimentales de la asociación entre anticonceptivos hormonales y cáncer inducido por el virus del papiloma humano. Es importante considerar los hallazgos biológicos porque en México el uso de anticonceptivos hormonales es muy amplio y la cantidad de casos de cáncer cervicouterino abundante y sólo los estudios epidemiológicos aclararán esta controversia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Galloway D. Is vaccination against human papillomavirus a possibility? Lancet 1998;351(suppl III):22-24.

  2. Walboomers J, Jacobs M, Manos M, Bosch F, Kummer J, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.

  3. Muñoz N, Bosch X. Cervical cancer and human papillomavirus: epidemiological evidence and perspectives for prevention. Salud Pública Mex 1997;39:274-282.

  4. Ho G, Bierman R, Beardsley L, Chang C, Burk D. Natural history of cervical papillomavirus infection in young women. N Eng J Med 1998;338:423-428.

  5. Tchabo J, Brinton L, Copeland C. Epp J. Determinants of genital human papilloma-viruses infection in low-income women in Washington D.C. Sex Trans Dis 1993;20:279-285.

  6. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, Shah K, et al. Epidemiology of HPV infection among mexican women with normal cervical citology. Int J Cancer 2001;91:412-420.

  7. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci 2005;102:2490-2495.

  8. Bradlow HL, Sepkovic DW. Steroid as procarcinogenic agents. Ann NY Acad Sci 2004;1028:216-232.

  9. Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes F, et al. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res 2000;60:1267-1275.

  10. Arbeit JM, Hoeley PM, Hanaham D. Chronic estrogen induced cervical and vaginal squamous carcinogenesis in HPV16 transgenic mice. Proc Natl Acad Sci USA 1996;93:2930-2935.

  11. Riley RR, Duensing S, Breake T, Munguer K, Lambert PF, et al. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Research 2003;63:4862-4871.

  12. Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci 2005;102:2490-2495.

  13. Delvene P, Herman L, Kholod N, Coberg JH, Herf M, et al. Role of hormone cofactors in the human papillomavirus-induced carcino-genesis of the uterine cervix. Mol Cell Endocrinol 2007;264:1-5.

  14. Strahle U, Klock G, Schutz G. A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proc Natl Acad Sci 1987;84:7871-7875.

  15. Chan W, Klock G, Bernard H. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol 1989;63:3261-3269.

  16. Antinone MJ, Birrer MJ, Patel D, Nader L, McCance DJ. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J 1996;15:1950-1960.

  17. Chon T, Chan W Bernard H. Transcrptional activation of human papillomavirus 16 by nuclear factor 1, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Research 1990;18:465-470.

  18. Men-Hsun Wu, Yi-Hsin Chan J, Pei-Yao Liu, Shu-Ting Liu, Shih-Ming Huang. Human papillomavirus E2 protein associates with nuclear receptors to stimulate nuclear receptor-and E2-dependent transcriptional activations in human cervical carcinoma cells. Int J Biochem & Cell Biol 2007;39:413-425.

  19. Díaz-González, Sacnité del Mar, Castro JI y Madrid-Marina V. Tesis de Maestría en Ciencias de la Salud Pública: Efecto del 17b-estradiol y progesterona en la proliferación de células cervicales y en la regulación de los oncogenes E6 y E7 del HPV-16. Instituto Nacional de Salud Pública. Junio 30, 2008.

  20. Men- Hsun Wu, James Yi-Hsin Chan, Pei-Yao Liu, Shu Ting Liu, Shih-Ming Huang. Human papillomavirus E2 protein associates with nuclear receptors to stimulate nuclear receptor- and E2-dependent transcriptional activations in human cervical carcinoma cells. Int. J Biochem 8i Cell Biol, 2007; 39:413-425.

  21. Chen YH, Huang LH, Chen TM. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophysics Res Commun 1996;224:651-659.

  22. Mittal R, Tsutsumi K, Pater A, Pater MM. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol 1993;81:5-12.

  23. Webster K, Taylor A, Gaston K. Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. J General Virol 2000;82:201-213.

  24. Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003;13:103-110.

  25. Moodley M, Sewart S, Herrington CS, Chetty R, Pegoraro R. The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression and cervical cancer. Int J Gynecol Cancer 2003;13:834-842.

  26. Shai A, Pitot HC, Lambert PF. P53 loss synergizes whit estrogen and papilomavirus oncogenes to induce cervical and breast cancers. Cancer Research 2008;68:2622-2631.

  27. Kumar A, Zhao Y, Meng G, Zeng M, et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator ADA3. Mol Cell Biol 2002;22:5801-5812.

  28. Meng G, Zhao Y, Nag A, Zeng M, et al. Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. J Biol Chem 2004;279:54230-54240.

  29. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008;110:S4-S7.

  30. Sanjosé S, Diaz M, Catellsagué X, Clifford G, Bruni L, et al. Worldwide prevalence and genotype distribution of cervical HPV in women with normal cytology. Lancet Infect Dis 2007;7:453-459.

  31. Restrepo HE, González J, Roberts E, Litvak J. Epidemiología y control del cáncer del cuello uterino en América Latina y el Caribe. Bol Of Sanit Panam 1987;102:578-592.

  32. SSA. Dirección General de Información y Evaluación del Desempeño. Secretaría de Salud. México 2001: Cancer Cervicouterino. SSA, 2002.

  33. Dirección General de Epidemiología. Secretaría de Salud. Registro histopatológico de neoplasias en México, 1994.

  34. Secretaría de Salud. Programa Nacional de Prevención y Control del Cáncer Cervicouterino 1995-2000. México, 1995.

  35. Bertram C. Evidence for practice: oral contraception and risk of cervical cancer. J Am Acad Nurse Pract 2004;16:455-461.

  36. McFarlnae N, Bazuaye PE, Jackson MD, Smikle M, Fletcher HM. Cervical Dysplasia and cancer and the use of hormonal contraceptives in Jamaica. BMC Women Health 2008;30:8-9.

  37. Deligeoroglou E, Michailidis E, CreatsasG. Oral contraceptive and reproductive system cancer. Ann NY Acad Sci 2003;997:199-208.

  38. MacFarlane-Anderson N, Bazuaye P, Jackson M, Smikle M, Fletcher H. Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women. BMC Women’s Health 2008;8:1-6.

  39. Vessey M, Painter R. Oral contraceptive use and cancer: findings in a large cohort study, l968-2004. Br J Cancer 2006;95:385-389.

  40. Appleby P, Beral V, Berrington A, Colin D, Francheschi S, et al. Cervical cancer an hormonal contraceptive. Lancet 2007;370:1591-1592.

  41. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomarirus infection: the IARC multicentric casecontrol study. Lancet 2002;359:1085-1092.

  42. Shapiro S, Rosenberg L, Hoffman M, Nelly JP, Cooper D, et al. Risk of invasive cancer of the cervix in relation to use of injectable progesterone contraceptives and combined estrogen/progesterone oral contraceptive. Cancer Causes Control 2003;14:485-495.

  43. Green J, Berrington A, Smith JS, Franceschi S, Appleby P, et al. Human papilloma-virus infection and use of oral contraceptive. Br J Cancer 2003;88:1713-1720.

  44. Juneja A, Sehgal A, Mitra AB, Pandey A. A survey on risk factors associated with cervical cancer. Indian J Cancer 2003;40:15-22.

  45. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003;9:348-359.

  46. Shields TS, Brinton LA, Burk RD, Wang SS, Weinstein SJ, et al. A case control study of risk factors for invasive cervical cancer among US women exposed to oncogenic types of HPV. Cancer Epidemiol Bio Prev 2004;13:1574-1582.




2020     |     www.medigraphic.com